T3067
Monoclonal Anti-TRAIL antibody produced in mouse
clone 75411, purified immunoglobulin, lyophilized powder
别名:
Anti-Apo-2L, Anti-TNF-Related Apoptosis-Inducing Ligand, Anti-TNFSF10
登录 查看组织和合同定价。
选择尺寸
关于此项目
Conjugate:
unconjugated
Clone:
75411, monoclonal
Application:
IHC (p), Neutral
Citations:
7
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
75411, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 8-25 μg/mL using human brain (occipital cortex) tissue sections, neutralization: 28 ng/mL using L929 mouse fibroblast cell line
isotype
IgG1
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... TNFSF10(8743)
General description
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. This ligand is a type II transmembrane protein that contains a short cytoplasmic N-terminal domain and a long C-terminal extracellular receptor-binding domain. TRAIL is highly expressed in immune system cells. The TRAIL gene is located on the human chromosome at 3q26.31.
Immunogen
purified, NSO-derived, recombinant human TRAIL extracellular domain.
Application
Monoclonal Anti-TRAIL antibody produced in mouse has been used in fluorescence-activated cell sorting (FACS).
Biochem/physiol Actions
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to TRAIL 1 & 2 receptors and induces apoptosis. This ligand is involved in the homeostasis of T-cells and natural killer (NK) cells. TRAIL also aids in the T-cell-mediated killing of virus-infected cells and oncogenic transformed cells.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
Devalingam Mahalingam et al.
Cancer treatment reviews, 35(3), 280-288 (2009-01-02)
Tumour necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumour necrosis factor (TNF) superfamily of cytokines that induces apoptosis upon binding to its death domain-containing transmembrane receptors, death receptors 4 and 5 (DR4, DR5). Importantly
ZhengQiang Yuan et al.
Journal of extracellular vesicles, 6(1), 1265291-1265291 (2017-03-23)
Extracellular vesicles (EVs) are lipid membrane-enclosed nanoparticles released by cells. They mediate intercellular communication by transferring biological molecules and therefore have potential as innovative drug delivery vehicles. TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of cancer cells. Unfortunately, the clinical
Djamel Aggoune et al.
Oncoscience, 1(1), 57-68 (2015-01-17)
Tyrosine kinase inhibitors (TKIs) have profoundly changed the natural history of chronic myeloid leukemia (CML). However, acquired resistance to imatinib, dasatinib or nilotinib (1(st) and 2(nd) generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These
Changhong Ke et al.
Cancers, 12(5) (2020-05-08)
Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a promising anti-cancer agent that rapidly induces apoptosis in cancer cells. Unfortunately, the clinical application of recombinant TRAIL (rTRAIL) has been hampered by its common cancer resistance. Naturally TRAIL is delivered
Christina Falschlehner et al.
The international journal of biochemistry & cell biology, 39(7-8), 1462-1475 (2007-04-04)
The TNF-related apoptosis-inducing ligand, TRAIL, has been shown to selectively kill tumour cells. This property has made TRAIL and agonistic antibodies against its death inducing receptors (TRAIL-R1 and TRAIL-R2) to some of the most promising novel biotherapeutic agents for cancer
相关内容
抗体的质量决定了整个免疫检测的成败， 是在选择抗体时首选的考虑因素。基于Sigma®、Chemicon®、Upstate®、Mil l ipore®、 Calbiochem®和Novagen®等子品牌的强强联合，默克在创新的 免疫原设计、免疫、挑选、筛选和验证等方面有着数十年的经验， 创造出许多被广泛使用的抗体，如4G10，Neun，组蛋白修饰等抗 体都是相关领域的“金标”抗体。 我们的技术和科研背景使默克成为高质量抗体的主要设计者和生产 者，而不仅仅是经销商。毋庸置疑，我们的每个小瓶中的抗体都包 含着大量的科学研究成果。
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持